View Past PerformancePrevest Denpro バランスシートの健全性財務の健全性 基準チェック /66Prevest Denproの総株主資本は₹1.2B 、総負債は₹0.0で、負債比率は0%となります。総資産と総負債はそれぞれ₹1.3Bと₹83.9Mです。 Prevest Denproの EBIT は₹227.0Mで、利息カバレッジ比率-6.2です。現金および短期投資は₹815.4Mです。主要情報0%負債資本比率₹0負債インタレスト・カバレッジ・レシオ-6.2x現金₹815.44mエクイティ₹1.25b負債合計₹83.93m総資産₹1.33b財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 30Prevest Denpro Limited Approves the Appointment of Pratul Gupta as Company Secretary and Compliance Officer, Effective May 27, 2026Prevest Denpro Limited informed that on the basis of the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, at its Meeting held on May 27, 2026, approved appointment of Mr. Pratul Gupta as Company Secretary & Compliance officer of the Company. Mr. Pratul Gupta is a qualified Company Secretary and Delhi University graduate with extensive experience in corporate compliance, NBFC regulations, SEBI regulations, and secretarial operations. He specializes in managing statutory filings, corporate actions, policy drafting, and regulatory liaison across listed companies, unlisted entities, and NBFCs.Reported Earnings • May 28Full year 2026 earnings released: EPS: ₹17.07 (vs ₹15.13 in FY 2025)Full year 2026 results: EPS: ₹17.07 (up from ₹15.13 in FY 2025). Revenue: ₹767.2m (up 22% from FY 2025). Net income: ₹204.9m (up 13% from FY 2025). Profit margin: 27% (down from 29% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • May 21Prevest Denpro Limited to Report Q4, 2026 Results on May 27, 2026Prevest Denpro Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 27, 2026Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹404, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 22x in the Medical Equipment industry in India. Total returns to shareholders of 26% over the past three years.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹3.93 (vs ₹3.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹3.93 (up from ₹3.77 in 3Q 2025). Revenue: ₹196.1m (up 31% from 3Q 2025). Net income: ₹47.2m (up 4.3% from 3Q 2025). Profit margin: 24% (down from 30% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year and the company’s share price has also increased by 10% per year.お知らせ • Feb 09Prevest Denpro Limited to Report Q3, 2026 Results on Feb 14, 2026Prevest Denpro Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 14, 2026Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹4.62 (vs ₹4.01 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.62 (up from ₹4.01 in 2Q 2025). Revenue: ₹198.3m (up 22% from 2Q 2025). Net income: ₹55.4m (up 15% from 2Q 2025). Profit margin: 28% (down from 30% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 10% per year.お知らせ • Nov 08Prevest Denpro Limited to Report Q2, 2026 Results on Nov 12, 2025Prevest Denpro Limited announced that they will report Q2, 2026 results on Nov 12, 2025New Risk • Sep 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹7.25b market cap, or US$82.3m).Upcoming Dividend • Aug 30Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 03 September 2025. Payment date: 09 October 2025. Payout ratio is a comfortable 6.6% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (1.6%).Declared Dividend • Aug 15Dividend of ₹1.00 announcedDividend of ₹1.00 is the same as last year. Ex-date: 3rd September 2025 Payment date: 9th October 2025 Dividend yield will be 0.2%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (9% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 23% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Aug 14Prevest Denpro Limited, Annual General Meeting, Sep 10, 2025Prevest Denpro Limited, Annual General Meeting, Sep 10, 2025.Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹3.67 (vs ₹3.06 in 1Q 2025)First quarter 2026 results: EPS: ₹3.67 (up from ₹3.06 in 1Q 2025). Revenue: ₹169.3m (up 27% from 1Q 2025). Net income: ₹44.1m (up 20% from 1Q 2025). Profit margin: 26% (down from 28% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 14Prevest Denpro Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025Prevest Denpro Limited at its board meeting held on August 13, 2025, recommended payment of Final Dividend on Equity Shares at the rate of 10% [that is, INR 1.00 (Rupees One Only) per Equity Share of Face Value of INR 10 (Rupees Ten Only)] for the Financial Year ended March 31, 2025, subject to approval of shareholders at the upcoming Annual General Meeting. The dividend, if approved, shall be paid within the prescribed timeline.お知らせ • Aug 09Prevest Denpro Limited to Report Q1, 2026 Results on Aug 13, 2025Prevest Denpro Limited announced that they will report Q1, 2026 results on Aug 13, 2025Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹542, the stock trades at a trailing P/E ratio of 35.8x. Average trailing P/E is 31x in the Medical Equipment industry in India. Total returns to shareholders of 87% over the past three years.Reported Earnings • May 28Full year 2025 earnings released: EPS: ₹15.13 (vs ₹13.44 in FY 2024)Full year 2025 results: EPS: ₹15.13 (up from ₹13.44 in FY 2024). Revenue: ₹670.9m (up 19% from FY 2024). Net income: ₹181.6m (up 13% from FY 2024). Profit margin: 27% (down from 29% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 16% per year.お知らせ • May 02Prevest Denpro Limited to Report Q4, 2025 Results on May 09, 2025Prevest Denpro Limited announced that they will report Q4, 2025 results on May 09, 2025Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹507, the stock trades at a trailing P/E ratio of 34.2x. Average trailing P/E is 22x in the Medical Equipment industry in India. Total returns to shareholders of 24% over the past three years.New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹5.19b market cap, or US$60.0m).Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹442, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 23x in the Medical Equipment industry in India. Total returns to shareholders of 20% over the past three years.Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹3.77 (vs ₹3.03 in 3Q 2024)Third quarter 2025 results: EPS: ₹3.77 (up from ₹3.03 in 3Q 2024). Revenue: ₹160.4m (up 18% from 3Q 2024). Net income: ₹45.3m (up 25% from 3Q 2024). Profit margin: 28% (up from 27% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 14% per year.Valuation Update With 7 Day Price Move • Jan 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹528, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 25x in the Medical Equipment industry in India. Total returns to shareholders of 36% over the past three years.お知らせ • Jan 28Prevest Denpro Limited to Report Q3, 2025 Results on Feb 01, 2025Prevest Denpro Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 01, 2025Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹4.01 (vs ₹3.04 in 2Q 2024)Second quarter 2025 results: EPS: ₹4.01 (up from ₹3.04 in 2Q 2024). Revenue: ₹173.1m (up 31% from 2Q 2024). Net income: ₹48.2m (up 32% from 2Q 2024). Profit margin: 28% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 05Prevest Denpro Limited to Report Q2, 2025 Results on Nov 11, 2024Prevest Denpro Limited announced that they will report Q2, 2025 results on Nov 11, 2024お知らせ • Sep 07Prevest Denpro Limited approves Final Dividend for the Financial Year Ended March 31, 2024Prevest Denpro Limited approved the declaration of Final Dividend at the rate of 10% [i.e.,1.00/- (Rupee One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] on Equity Shares for the Financial Year ended March 31, 2024, at its AGM, held on September 06, 2024.Declared Dividend • Aug 23Dividend of ₹1.00 announcedDividend of ₹1.00 is the same as last year. Ex-date: 30th August 2024 Payment date: 6th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (15% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 31% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Aug 09Prevest Denpro Limited, Annual General Meeting, Sep 06, 2024Prevest Denpro Limited, Annual General Meeting, Sep 06, 2024.Reported Earnings • Aug 09First quarter 2025 earnings released: EPS: ₹3.06 (vs ₹3.40 in 1Q 2024)First quarter 2025 results: EPS: ₹3.06 (down from ₹3.40 in 1Q 2024). Revenue: ₹142.2m (up 6.2% from 1Q 2024). Net income: ₹36.7m (down 10% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by higher expenses.お知らせ • Aug 08Prevest Denpro Limited Declares Final Dividend for the Financial Year Ended March 31, 2024Prevest Denpro Limited at its AGM, held on August 8, 2024, declared Final Dividend at the rate of 10% [i.e.,1.00/- (Rupee One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] on Equity Shares for the Financial Year ended March 31, 2024.お知らせ • Jul 31Prevest Denpro Limited to Report Q1, 2025 Final Results on Aug 08, 2024Prevest Denpro Limited announced that they will report Q1, 2025 final results on Aug 08, 2024Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹591, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 26x in the Medical Equipment industry in India. Total returns to shareholders of 11% over the past year.New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹6.67b market cap, or US$79.9m).Valuation Update With 7 Day Price Move • Jun 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹448, the stock trades at a trailing P/E ratio of 33.3x. Average trailing P/E is 25x in the Medical Equipment industry in India. Total returns to shareholders of 6.2% over the past year.Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹13.45 (vs ₹13.09 in FY 2023)Full year 2024 results: EPS: ₹13.45 (up from ₹13.09 in FY 2023). Revenue: ₹592.9m (up 19% from FY 2023). Net income: ₹161.4m (up 2.7% from FY 2023). Profit margin: 27% (down from 32% in FY 2023). The decrease in margin was driven by higher expenses.お知らせ • May 05Prevest Denpro Limited to Report Q4, 2024 Results on May 10, 2024Prevest Denpro Limited announced that they will report Q4, 2024 results on May 10, 2024Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹440, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 30x in the Medical Equipment industry in India. Total returns to shareholders of 36% over the past year.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹406, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 25x in the Medical Equipment industry in India. Total returns to shareholders of 33% over the past year.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹427, the stock trades at a trailing P/E ratio of 31.2x. Average trailing P/E is 26x in the Medical Equipment industry in India. Total returns to shareholders of 32% over the past year.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹372, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 28x in the Medical Equipment industry in India. Total returns to shareholders of 7.3% over the past year.お知らせ • Jan 25Prevest Denpro Limited to Report Q3, 2024 Results on Feb 03, 2024Prevest Denpro Limited announced that they will report Q3, 2024 results at 12:15 PM, Indian Standard Time on Feb 03, 2024お知らせ • Nov 25Prevest Denpro Limited Launches Oradox Advanced Oral Care Range of Innovative Oral Hygiene Products At the World Dental Show, Mumbai 2023Prevest Denpro Limited launched its revolutionary oral care product segment, Oradox, at the World Dental Show on 19th Nov. 2023. A large number of dental professionals, experts and enthusiasts from around the world witnessed the launching of Oradox products. Oradox represents a cutting-edge advancement in oral health, embodying Prevest Denpro Limited's commitment to delivering innovative and effective solutions for dental care. The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care. Oradox brought together science and innovation to address the diverse needs of the dental professionals & consumers in the realm of dental health. Oradox stood out with its emphasis on research-backed formulations, quality ingredients, and a commitment to delivering predictable results. The product line addressed various aspects of oral health, including cavity protection, gum care, enamel strength, and breath freshness. Prevest Denpro Limited invited dental practitioners, retailers, and consumers to explore the Oradox brand and discover a new era of oral care excellence. The launch at the World Dental Show signified the company's dedication to staying at the forefront of dental innovation and providing solutions that made a positive impact on oral health worldwide.お知らせ • Oct 28Prevest Denpro Limited to Report Q2, 2024 Results on Nov 03, 2023Prevest Denpro Limited announced that they will report Q2, 2024 results on Nov 03, 2023お知らせ • Sep 07Prevest Denpro Limited Approves Appointment of Aman Sadhotra as the Company Secretary and Compliance OfficerPrevest Denpro Limited announced that at its board meeting held on September 01, 2023, on the recommendation of nomination and remuneration committee has approved the appointment of Mr. Aman Sadhotra as the company secretary and compliance officer of the company from September 01, 2023. Mr. Aman Sadhotra is a qualified. Company Secretary (ICSI Membership No.: A66562). He holds a postgraduate degree in Investment Banking from the London Governance and Compliance Academy, along with a BCom degree from Delhi University. With a proven track record in handling various compliance matters, Mr. Sadhotra is an ideal choice for the role of Company Secretary cum Compliance Officer. His strong educational background and experience make him well-equipped to ensure the company's adherence to all regulatory requirements and governance standards.お知らせ • Sep 05Prevest Denpro Limited Announces Resignation of Krishna Rathi from Company Secretary and Compliance OfficerPrevest Denpro Limited announced resignation of Krishna Rathi from the post of Company Secretary and Compliance Officer of the Company due to pre occupaney in other assignments. The Board is kindly requested to accept my resignation with effect from August 31, 2023 and take the same on your records.お知らせ • Sep 01Prevest Denpro Limited Declares Final Dividend for the Financial Year Ended March 31, 2023Prevest Denpro Limited at its AGM, held on August 30, 2023, declared Final Dividend at the rate of 10% [i.e.,1.00/- (Rupee One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] on Equity Shares for the Financial Year ended March 31, 2023.お知らせ • Aug 04+ 1 more updatePrevest Denpro Limited, Annual General Meeting, Aug 30, 2023Prevest Denpro Limited, Annual General Meeting, Aug 30, 2023.Reported Earnings • Aug 04First quarter 2024 earnings released: EPS: ₹3.40 (vs ₹3.07 in 1Q 2023)First quarter 2024 results: EPS: ₹3.40 (up from ₹3.07 in 1Q 2023). Revenue: ₹140.0m (up 14% from 1Q 2023). Net income: ₹40.8m (up 11% from 1Q 2023). Profit margin: 29% (in line with 1Q 2023).お知らせ • Jul 29Prevest Denpro Limited to Report Q1, 2024 Results on Aug 03, 2023Prevest Denpro Limited announced that they will report Q1, 2024 results on Aug 03, 2023Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹512, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 23x in the Medical Equipment industry in India. Total returns to shareholders of 77% over the past year.Reported Earnings • Apr 29Full year 2023 earnings released: EPS: ₹13.09 (vs ₹9.64 in FY 2022)Full year 2023 results: EPS: ₹13.09 (up from ₹9.64 in FY 2022). Revenue: ₹518.9m (up 36% from FY 2022). Net income: ₹157.1m (up 36% from FY 2022). Profit margin: 30% (in line with FY 2022).Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹404, the stock trades at a trailing P/E ratio of 37.1x. Average trailing P/E is 26x in the Medical Equipment industry in India. Total returns to shareholders of 4.3% over the past year.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹320, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 25x in the Medical Equipment industry in India. Total loss to shareholders of 20% over the past year.Reported Earnings • Feb 15Third quarter 2023 earnings released: EPS: ₹2.99 (vs ₹3.13 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.99 (down from ₹3.13 in 3Q 2022). Revenue: ₹122.7m (up 10% from 3Q 2022). Net income: ₹35.9m (down 4.4% from 3Q 2022). Profit margin: 29% (down from 34% in 3Q 2022). The decrease in margin was driven by higher expenses.お知らせ • Feb 07Prevest Denpro Limited to Report Q3, 2023 Results on Feb 13, 2023Prevest Denpro Limited announced that they will report Q3, 2023 results on Feb 13, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Sudeep Murthy was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 10Second quarter 2023 earnings released: EPS: ₹2.78 (vs ₹3.13 in 2Q 2022)Second quarter 2023 results: EPS: ₹2.78 (down from ₹3.13 in 2Q 2022). Revenue: ₹120.3m (up 8.1% from 2Q 2022). Net income: ₹33.3m (down 11% from 2Q 2022). Profit margin: 28% (down from 34% in 2Q 2022). The decrease in margin was driven by higher expenses.お知らせ • Nov 05Prevest Denpro Limited to Report Q2, 2023 Results on Nov 09, 2022Prevest Denpro Limited announced that they will report Q2, 2023 results on Nov 09, 2022お知らせ • Aug 29Prevest Denpro Limited Appoints Krishna Rathi as Company Secretary and Compliance OfficerPrevest Denpro Limited announced that on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company at their meeting held on August 27, 2022, have approved the appointment of Ms. Krishna Rathi, with effect from August 27, 2022 as the Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company, pursuant to the provisions of Section 203 of the Companies Act, 2013 and Regulation 6(1) of SEBI LODR 2015. Ms. Krishna Rathi has more than 5 years of post-qualification experience of working listed companies. She has experience in managing secretarial functions and compliance matters ensuring that company complies and operates in accordance with statutory and legal provisions.お知らせ • Aug 25Prevest Denpro Limited, Annual General Meeting, Sep 16, 2022Prevest Denpro Limited, Annual General Meeting, Sep 16, 2022, at 12:30 Indian Standard Time. Agenda: To receive, consider, approve and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2022, together with the reports of the Board of Directors and Auditors thereon; and to consider directorate reelections;.お知らせ • Aug 10Prevest Denpro Limited Announces Resignation of Komal Mehra from the Post of Company Secretary and Compliance OfficerPrevest Denpro Limited announced resignation of Komal Mehra from the post of Company Secretary and Compliance Officer of the Company due to pre-occupancy in other assignments.お知らせ • May 12Prevest Denpro Limited to Report Fiscal Year 2022 Results on May 17, 2022Prevest Denpro Limited announced that they will report fiscal year 2022 results on May 17, 2022Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Sudeep Murthy was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). CFO & Whole Time Director Namrata Modi is the most experienced director on the board, commencing their role in 1999. Non-Executive Independent Director Sudeep Murthy was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.財務状況分析短期負債: 543363の 短期資産 ( ₹1.1B ) が 短期負債 ( ₹71.4M ) を超えています。長期負債: 543363の短期資産 ( ₹1.1B ) が 長期負債 ( ₹12.5M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: 543363は負債がありません。負債の削減: 543363負債比率が6.2%であった 5 年前と比べて負債がありません。債務返済能力: 543363には負債がないため、営業キャッシュフロー でカバーする必要はありません。インタレストカバレッジ: 543363には負債がないため、利息支払い の負担は問題になりません。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YHealthcare 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 19:19終値2026/06/16 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Prevest Denpro Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 30Prevest Denpro Limited Approves the Appointment of Pratul Gupta as Company Secretary and Compliance Officer, Effective May 27, 2026Prevest Denpro Limited informed that on the basis of the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, at its Meeting held on May 27, 2026, approved appointment of Mr. Pratul Gupta as Company Secretary & Compliance officer of the Company. Mr. Pratul Gupta is a qualified Company Secretary and Delhi University graduate with extensive experience in corporate compliance, NBFC regulations, SEBI regulations, and secretarial operations. He specializes in managing statutory filings, corporate actions, policy drafting, and regulatory liaison across listed companies, unlisted entities, and NBFCs.
Reported Earnings • May 28Full year 2026 earnings released: EPS: ₹17.07 (vs ₹15.13 in FY 2025)Full year 2026 results: EPS: ₹17.07 (up from ₹15.13 in FY 2025). Revenue: ₹767.2m (up 22% from FY 2025). Net income: ₹204.9m (up 13% from FY 2025). Profit margin: 27% (down from 29% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • May 21Prevest Denpro Limited to Report Q4, 2026 Results on May 27, 2026Prevest Denpro Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 27, 2026
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹404, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 22x in the Medical Equipment industry in India. Total returns to shareholders of 26% over the past three years.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹3.93 (vs ₹3.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹3.93 (up from ₹3.77 in 3Q 2025). Revenue: ₹196.1m (up 31% from 3Q 2025). Net income: ₹47.2m (up 4.3% from 3Q 2025). Profit margin: 24% (down from 30% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year and the company’s share price has also increased by 10% per year.
お知らせ • Feb 09Prevest Denpro Limited to Report Q3, 2026 Results on Feb 14, 2026Prevest Denpro Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 14, 2026
Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹4.62 (vs ₹4.01 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.62 (up from ₹4.01 in 2Q 2025). Revenue: ₹198.3m (up 22% from 2Q 2025). Net income: ₹55.4m (up 15% from 2Q 2025). Profit margin: 28% (down from 30% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 10% per year.
お知らせ • Nov 08Prevest Denpro Limited to Report Q2, 2026 Results on Nov 12, 2025Prevest Denpro Limited announced that they will report Q2, 2026 results on Nov 12, 2025
New Risk • Sep 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹7.25b market cap, or US$82.3m).
Upcoming Dividend • Aug 30Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 03 September 2025. Payment date: 09 October 2025. Payout ratio is a comfortable 6.6% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (1.6%).
Declared Dividend • Aug 15Dividend of ₹1.00 announcedDividend of ₹1.00 is the same as last year. Ex-date: 3rd September 2025 Payment date: 9th October 2025 Dividend yield will be 0.2%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (9% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 23% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Aug 14Prevest Denpro Limited, Annual General Meeting, Sep 10, 2025Prevest Denpro Limited, Annual General Meeting, Sep 10, 2025.
Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹3.67 (vs ₹3.06 in 1Q 2025)First quarter 2026 results: EPS: ₹3.67 (up from ₹3.06 in 1Q 2025). Revenue: ₹169.3m (up 27% from 1Q 2025). Net income: ₹44.1m (up 20% from 1Q 2025). Profit margin: 26% (down from 28% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 14Prevest Denpro Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025Prevest Denpro Limited at its board meeting held on August 13, 2025, recommended payment of Final Dividend on Equity Shares at the rate of 10% [that is, INR 1.00 (Rupees One Only) per Equity Share of Face Value of INR 10 (Rupees Ten Only)] for the Financial Year ended March 31, 2025, subject to approval of shareholders at the upcoming Annual General Meeting. The dividend, if approved, shall be paid within the prescribed timeline.
お知らせ • Aug 09Prevest Denpro Limited to Report Q1, 2026 Results on Aug 13, 2025Prevest Denpro Limited announced that they will report Q1, 2026 results on Aug 13, 2025
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹542, the stock trades at a trailing P/E ratio of 35.8x. Average trailing P/E is 31x in the Medical Equipment industry in India. Total returns to shareholders of 87% over the past three years.
Reported Earnings • May 28Full year 2025 earnings released: EPS: ₹15.13 (vs ₹13.44 in FY 2024)Full year 2025 results: EPS: ₹15.13 (up from ₹13.44 in FY 2024). Revenue: ₹670.9m (up 19% from FY 2024). Net income: ₹181.6m (up 13% from FY 2024). Profit margin: 27% (down from 29% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 16% per year.
お知らせ • May 02Prevest Denpro Limited to Report Q4, 2025 Results on May 09, 2025Prevest Denpro Limited announced that they will report Q4, 2025 results on May 09, 2025
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹507, the stock trades at a trailing P/E ratio of 34.2x. Average trailing P/E is 22x in the Medical Equipment industry in India. Total returns to shareholders of 24% over the past three years.
New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹5.19b market cap, or US$60.0m).
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹442, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 23x in the Medical Equipment industry in India. Total returns to shareholders of 20% over the past three years.
Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹3.77 (vs ₹3.03 in 3Q 2024)Third quarter 2025 results: EPS: ₹3.77 (up from ₹3.03 in 3Q 2024). Revenue: ₹160.4m (up 18% from 3Q 2024). Net income: ₹45.3m (up 25% from 3Q 2024). Profit margin: 28% (up from 27% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 14% per year.
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹528, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 25x in the Medical Equipment industry in India. Total returns to shareholders of 36% over the past three years.
お知らせ • Jan 28Prevest Denpro Limited to Report Q3, 2025 Results on Feb 01, 2025Prevest Denpro Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 01, 2025
Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹4.01 (vs ₹3.04 in 2Q 2024)Second quarter 2025 results: EPS: ₹4.01 (up from ₹3.04 in 2Q 2024). Revenue: ₹173.1m (up 31% from 2Q 2024). Net income: ₹48.2m (up 32% from 2Q 2024). Profit margin: 28% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 05Prevest Denpro Limited to Report Q2, 2025 Results on Nov 11, 2024Prevest Denpro Limited announced that they will report Q2, 2025 results on Nov 11, 2024
お知らせ • Sep 07Prevest Denpro Limited approves Final Dividend for the Financial Year Ended March 31, 2024Prevest Denpro Limited approved the declaration of Final Dividend at the rate of 10% [i.e.,1.00/- (Rupee One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] on Equity Shares for the Financial Year ended March 31, 2024, at its AGM, held on September 06, 2024.
Declared Dividend • Aug 23Dividend of ₹1.00 announcedDividend of ₹1.00 is the same as last year. Ex-date: 30th August 2024 Payment date: 6th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (15% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 31% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Aug 09Prevest Denpro Limited, Annual General Meeting, Sep 06, 2024Prevest Denpro Limited, Annual General Meeting, Sep 06, 2024.
Reported Earnings • Aug 09First quarter 2025 earnings released: EPS: ₹3.06 (vs ₹3.40 in 1Q 2024)First quarter 2025 results: EPS: ₹3.06 (down from ₹3.40 in 1Q 2024). Revenue: ₹142.2m (up 6.2% from 1Q 2024). Net income: ₹36.7m (down 10% from 1Q 2024). Profit margin: 26% (down from 31% in 1Q 2024). The decrease in margin was driven by higher expenses.
お知らせ • Aug 08Prevest Denpro Limited Declares Final Dividend for the Financial Year Ended March 31, 2024Prevest Denpro Limited at its AGM, held on August 8, 2024, declared Final Dividend at the rate of 10% [i.e.,1.00/- (Rupee One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] on Equity Shares for the Financial Year ended March 31, 2024.
お知らせ • Jul 31Prevest Denpro Limited to Report Q1, 2025 Final Results on Aug 08, 2024Prevest Denpro Limited announced that they will report Q1, 2025 final results on Aug 08, 2024
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹591, the stock trades at a trailing P/E ratio of 44x. Average trailing P/E is 26x in the Medical Equipment industry in India. Total returns to shareholders of 11% over the past year.
New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹6.67b market cap, or US$79.9m).
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹448, the stock trades at a trailing P/E ratio of 33.3x. Average trailing P/E is 25x in the Medical Equipment industry in India. Total returns to shareholders of 6.2% over the past year.
Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹13.45 (vs ₹13.09 in FY 2023)Full year 2024 results: EPS: ₹13.45 (up from ₹13.09 in FY 2023). Revenue: ₹592.9m (up 19% from FY 2023). Net income: ₹161.4m (up 2.7% from FY 2023). Profit margin: 27% (down from 32% in FY 2023). The decrease in margin was driven by higher expenses.
お知らせ • May 05Prevest Denpro Limited to Report Q4, 2024 Results on May 10, 2024Prevest Denpro Limited announced that they will report Q4, 2024 results on May 10, 2024
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹440, the stock trades at a trailing P/E ratio of 32.1x. Average trailing P/E is 30x in the Medical Equipment industry in India. Total returns to shareholders of 36% over the past year.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹406, the stock trades at a trailing P/E ratio of 29.6x. Average trailing P/E is 25x in the Medical Equipment industry in India. Total returns to shareholders of 33% over the past year.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹427, the stock trades at a trailing P/E ratio of 31.2x. Average trailing P/E is 26x in the Medical Equipment industry in India. Total returns to shareholders of 32% over the past year.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹372, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 28x in the Medical Equipment industry in India. Total returns to shareholders of 7.3% over the past year.
お知らせ • Jan 25Prevest Denpro Limited to Report Q3, 2024 Results on Feb 03, 2024Prevest Denpro Limited announced that they will report Q3, 2024 results at 12:15 PM, Indian Standard Time on Feb 03, 2024
お知らせ • Nov 25Prevest Denpro Limited Launches Oradox Advanced Oral Care Range of Innovative Oral Hygiene Products At the World Dental Show, Mumbai 2023Prevest Denpro Limited launched its revolutionary oral care product segment, Oradox, at the World Dental Show on 19th Nov. 2023. A large number of dental professionals, experts and enthusiasts from around the world witnessed the launching of Oradox products. Oradox represents a cutting-edge advancement in oral health, embodying Prevest Denpro Limited's commitment to delivering innovative and effective solutions for dental care. The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care. Oradox brought together science and innovation to address the diverse needs of the dental professionals & consumers in the realm of dental health. Oradox stood out with its emphasis on research-backed formulations, quality ingredients, and a commitment to delivering predictable results. The product line addressed various aspects of oral health, including cavity protection, gum care, enamel strength, and breath freshness. Prevest Denpro Limited invited dental practitioners, retailers, and consumers to explore the Oradox brand and discover a new era of oral care excellence. The launch at the World Dental Show signified the company's dedication to staying at the forefront of dental innovation and providing solutions that made a positive impact on oral health worldwide.
お知らせ • Oct 28Prevest Denpro Limited to Report Q2, 2024 Results on Nov 03, 2023Prevest Denpro Limited announced that they will report Q2, 2024 results on Nov 03, 2023
お知らせ • Sep 07Prevest Denpro Limited Approves Appointment of Aman Sadhotra as the Company Secretary and Compliance OfficerPrevest Denpro Limited announced that at its board meeting held on September 01, 2023, on the recommendation of nomination and remuneration committee has approved the appointment of Mr. Aman Sadhotra as the company secretary and compliance officer of the company from September 01, 2023. Mr. Aman Sadhotra is a qualified. Company Secretary (ICSI Membership No.: A66562). He holds a postgraduate degree in Investment Banking from the London Governance and Compliance Academy, along with a BCom degree from Delhi University. With a proven track record in handling various compliance matters, Mr. Sadhotra is an ideal choice for the role of Company Secretary cum Compliance Officer. His strong educational background and experience make him well-equipped to ensure the company's adherence to all regulatory requirements and governance standards.
お知らせ • Sep 05Prevest Denpro Limited Announces Resignation of Krishna Rathi from Company Secretary and Compliance OfficerPrevest Denpro Limited announced resignation of Krishna Rathi from the post of Company Secretary and Compliance Officer of the Company due to pre occupaney in other assignments. The Board is kindly requested to accept my resignation with effect from August 31, 2023 and take the same on your records.
お知らせ • Sep 01Prevest Denpro Limited Declares Final Dividend for the Financial Year Ended March 31, 2023Prevest Denpro Limited at its AGM, held on August 30, 2023, declared Final Dividend at the rate of 10% [i.e.,1.00/- (Rupee One Only) per Equity Share of Face Value of 10/- (Rupees Ten Only)] on Equity Shares for the Financial Year ended March 31, 2023.
お知らせ • Aug 04+ 1 more updatePrevest Denpro Limited, Annual General Meeting, Aug 30, 2023Prevest Denpro Limited, Annual General Meeting, Aug 30, 2023.
Reported Earnings • Aug 04First quarter 2024 earnings released: EPS: ₹3.40 (vs ₹3.07 in 1Q 2023)First quarter 2024 results: EPS: ₹3.40 (up from ₹3.07 in 1Q 2023). Revenue: ₹140.0m (up 14% from 1Q 2023). Net income: ₹40.8m (up 11% from 1Q 2023). Profit margin: 29% (in line with 1Q 2023).
お知らせ • Jul 29Prevest Denpro Limited to Report Q1, 2024 Results on Aug 03, 2023Prevest Denpro Limited announced that they will report Q1, 2024 results on Aug 03, 2023
Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹512, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 23x in the Medical Equipment industry in India. Total returns to shareholders of 77% over the past year.
Reported Earnings • Apr 29Full year 2023 earnings released: EPS: ₹13.09 (vs ₹9.64 in FY 2022)Full year 2023 results: EPS: ₹13.09 (up from ₹9.64 in FY 2022). Revenue: ₹518.9m (up 36% from FY 2022). Net income: ₹157.1m (up 36% from FY 2022). Profit margin: 30% (in line with FY 2022).
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹404, the stock trades at a trailing P/E ratio of 37.1x. Average trailing P/E is 26x in the Medical Equipment industry in India. Total returns to shareholders of 4.3% over the past year.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹320, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 25x in the Medical Equipment industry in India. Total loss to shareholders of 20% over the past year.
Reported Earnings • Feb 15Third quarter 2023 earnings released: EPS: ₹2.99 (vs ₹3.13 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.99 (down from ₹3.13 in 3Q 2022). Revenue: ₹122.7m (up 10% from 3Q 2022). Net income: ₹35.9m (down 4.4% from 3Q 2022). Profit margin: 29% (down from 34% in 3Q 2022). The decrease in margin was driven by higher expenses.
お知らせ • Feb 07Prevest Denpro Limited to Report Q3, 2023 Results on Feb 13, 2023Prevest Denpro Limited announced that they will report Q3, 2023 results on Feb 13, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Sudeep Murthy was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 10Second quarter 2023 earnings released: EPS: ₹2.78 (vs ₹3.13 in 2Q 2022)Second quarter 2023 results: EPS: ₹2.78 (down from ₹3.13 in 2Q 2022). Revenue: ₹120.3m (up 8.1% from 2Q 2022). Net income: ₹33.3m (down 11% from 2Q 2022). Profit margin: 28% (down from 34% in 2Q 2022). The decrease in margin was driven by higher expenses.
お知らせ • Nov 05Prevest Denpro Limited to Report Q2, 2023 Results on Nov 09, 2022Prevest Denpro Limited announced that they will report Q2, 2023 results on Nov 09, 2022
お知らせ • Aug 29Prevest Denpro Limited Appoints Krishna Rathi as Company Secretary and Compliance OfficerPrevest Denpro Limited announced that on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company at their meeting held on August 27, 2022, have approved the appointment of Ms. Krishna Rathi, with effect from August 27, 2022 as the Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company, pursuant to the provisions of Section 203 of the Companies Act, 2013 and Regulation 6(1) of SEBI LODR 2015. Ms. Krishna Rathi has more than 5 years of post-qualification experience of working listed companies. She has experience in managing secretarial functions and compliance matters ensuring that company complies and operates in accordance with statutory and legal provisions.
お知らせ • Aug 25Prevest Denpro Limited, Annual General Meeting, Sep 16, 2022Prevest Denpro Limited, Annual General Meeting, Sep 16, 2022, at 12:30 Indian Standard Time. Agenda: To receive, consider, approve and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2022, together with the reports of the Board of Directors and Auditors thereon; and to consider directorate reelections;.
お知らせ • Aug 10Prevest Denpro Limited Announces Resignation of Komal Mehra from the Post of Company Secretary and Compliance OfficerPrevest Denpro Limited announced resignation of Komal Mehra from the post of Company Secretary and Compliance Officer of the Company due to pre-occupancy in other assignments.
お知らせ • May 12Prevest Denpro Limited to Report Fiscal Year 2022 Results on May 17, 2022Prevest Denpro Limited announced that they will report fiscal year 2022 results on May 17, 2022
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Sudeep Murthy was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). CFO & Whole Time Director Namrata Modi is the most experienced director on the board, commencing their role in 1999. Non-Executive Independent Director Sudeep Murthy was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.